primary endocrine therapy
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer
... One third of new breast cancer diagnoses occur in women aged over 70 years in the UK [1].. Increasing age results in rising rates of comorbidity and frailty [2] so tolerance to some standard breast cancer therapies may ...
19
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
... towards primary tamoxifen treatment was based on the premise that older women are less likely to be fit for ...or primary endocrine therapy, such as avoidance of hospitalisation, fear of ...
36
Information needs of older women faced with a choice of primary endocrine therapy or surgery for early stage breast cancer : a literature review
... Abstract Primary endocrine therapy (PET) as an alternative to surgery is widely used in the UK for the treatment of older women with operable breast ...operable primary breast cancer, and ...
11
Information needs and decision making preferences of older women offered a choice between surgery and primary endocrine therapy for early breast cancer
... that primary endocrine therapy (PET) should only be offered if “significant comorbidity precludes surgery” and that age alone should not affect the decision ...
16
Information needs and decision-making preferences of older women offered a choice between surgery and primary endocrine therapy for early breast cancer
... that primary endocrine therapy (PET) should only be offered if “significant comorbidity precludes surgery” and that age alone should not affect the decision ...
17
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer
... after primary endocrine therapy were collected from each patient for immunohistochemical (IHC) ...of primary antibodies) were used as a quality control of the ...
15
Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
... the primary endocrine therapy arms may have performed better against surgery arm plus endocrine ...and endocrine therapy (Willsher et al, ...
5
Efficient development and usability testing of decision support interventions for older women with breast cancer
... Generally, the feedback was positive about the primary endocrine therapy / surgery+endocrine therapy DESI. Both the brief decision aid and booklet were understood and mostly clear (A). ...
13
VAV3 mediates resistance to breast cancer endocrine therapy
... with primary endocrine therapy before surgical excision of breast tumors were chosen from the clinical database activity of the Catalan Institute of Oncology (ICO) Breast Cancer ...received ...
16
Efficient development and usability testing of decision support interventions for older women with breast cancer
... Patients facing the decision only DESI-S, Primary endocrine therapy/surgery+endocrine therapy DESI; DESI-C, chemotherapy DESI; Bo, booklet; Br, brief decision aid; SUT, Primary endocrine[r] ...
37
Roscovitine confers tumor suppressive effect on therapy resistant breast tumor cells
... Introduction: Current clinical strategies for treating hormonal breast cancer involve the use of anti-estrogens that block estrogen receptor (ER) a functions and aromatase inhibitors that decrease local and systemic ...
11
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
... with endocrine therapy versus chemotherapy (capecitabine) in postmenopausal patients with ER-positive HER2-negative metastatic breast cancer, who showed resistance to aromatase inhibitors (NCT02028507, ...
26
The interaction between ER and NFκB in resistance to endocrine therapy
... crine therapy, which is the mainstay of treatment for patients with ER-positive breast ...between endocrine therapy resistance and activated growth factor signaling pathways (for example, ...
14
Optimising endocrine therapy in postmenopausal women with advanced breast cancer
... 2012 Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast[r] ...
26
Oncology providers’ perspectives on endocrine therapy prescribing and management
... of therapy and also to make sure the patient understands what we are talking about when we talk about ...no therapy at all, is that risk 40 percent or 4 percent? And then your net gain from using ET is ...
13
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
... chemo- therapy, distant recurrence was reported in 26 patients ...adjuvant endocrine therapy was predominantly associated with lower risks of local, regional, and contralateral breast cancer events, ...
16
SOME COMPLICATIONS OF TRANSFUSION, ENDOCRINE THERAPY AND OXYGEN ADMINISTRATION
... However, supposedly normal donors gave blood re- subting in the same incidence of jaundice in the recipient1. Such figures indicate that a history of jaundice is an indication for reject[r] ...
7
The effects of naloxone on human breast cancer progression: in vitro and in vivo studies on MDA.MB231 cells
... Conventional endocrine therapy and HER2 targeted therapy on patients with TNBC fail because these patients lack both hormone receptors and do not express ...
7
C myc, not HER 2/neu, can predict recurrence and mortality of patients with node negative breast cancer
... 15. Bianco AR, Laurentils MD, Carlomagno C, Lauria R, Petrella G, Panico L, Pettinato G, Perrone F, Gallo C, Marinelli A, Placido SD: 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: ...
7
Personalizing the treatment of women with early breast cancer_Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013.pdf
... The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of trials of chemotherapy versus no chemotherapy [18] failed to de fi ne any group for which chemotherapy did not offer an advantage. This ...
18